Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy
Table 3
Median (1st quartile–3rd quartile) computed for mean blur rate of all areas (MA), mean blur rate of vascular area (MV), mean blur rate of tissue area (MT), mean blur rate (MBR), relative flow volume (RFV) at baseline, time 1 (T1), and time 2 (T2).
Variables
Baseline
T1
Relative change
T2
Relative change
Friedman test
(T1 vs. Baseline)
(T2 vs. T1)
value
MA (AU)
25.0 (21.1–31.5)
19.7 (18.7–23.0)
−22.8 (−26.1; −6.9)
19.6 (18.3–26.3)
0 (−14.3; −5.1)
0.046
MT (AU)
14.6 (12.9–15.7)
12.0 (11.5–15.4)
−8.7 (−18.9; −4.3)
11.6 (11.2–15.0)
−2.3 (−2.88; −2.0)
0.023
MV (AU)
46.1 (40.3–55.9)
40.4 (36.5–46.5)
−13.1 (−21.2; −1.6)
39.7 (35.8–45.9)
−1.4 (−1.8; −1.0)
0.025
MBR2 (AU)
20.9 (18.0–23.7)
18.5 (15.5–20.3)
−17.1 (−26.7; −1.7)
16.0 (13.4–20.3)
−8.0 (−6.4; −19.7)
0.004
MBR3 (AU)
20.9 (20.1–25.1)
19.4 (18.4–22.1)
−6.3 (−7.9; −2.6)
20.6 (17.7–20.9)
−4.3 (−14.4; −10.8)
0.010
RFV2 (AU)
269.5 (221.6–285.5)
173.8 (126.1–206.2)
−8.9 (−44.8; −9.2)
199.7 (152.4–204.7)
10.8 (−19.7; −3.5)
0.292
RFV3 (AU)
306.8 (285.6–372.4)
263.2 (226.4–268.4)
−14.0 (−21.3; −7.2)
259.1 (140.9–336.8)
−6.1 (−19.3; −28.7)
0.002
nonparametric pairwise multiple comparisons versus previous evaluation time.
